Vertex Pharmaceuticals Incorporated
NASDAQVRTX heads into its Q1 2026 results — scheduled for May 13 — with options traders at their most defensive in months, even as the Street raised price targets and the lending market remains wide open. The clearest signal this week is in options. Put demand has risen sharply relative to calls, pushing the put/call ratio to 0.93, more than two standard deviations above its 20-day…
Snapshot as of 6 May 2026
VRTX heads into its Q1 2026 results — scheduled for May 13 — with options traders at their most defensive in months, even as the Street raised price targets and the lending market remains wide open. The clearest signal…
Vertex Pharmaceuticals arrives at its May 4 Q1 2026 earnings report carrying a 28.5% gap between where the stock trades and where most analysts believe it belongs. The bullish analyst thesis remains firmly intact…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for VRTX — free to start on ORTEX.
Sign up for free →Open VRTX on ORTEX